Review proposal - August 2009

Review of NICE Technology Appraisal Guidance No TA110; Rituximab for the treatment of follicular lymphoma

As you may be aware the planned date for review of the above guidance was July 2009.

This is the date at when the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake an update of the existing guidance.

The Institute has carried out a search for information relevant to this appraisal, and believes that it is appropriate for the guidance to be updated and the update should include consideration of the extension of the license (covering a wider range of chemotherapy regimens).

In order to be completely confident that this is appropriate, we are asking   consultees and commentators with an interest in this topic, to inform us of any evidence which would suggest that an earlier review would be beneficial.  We would particularly like to be made aware of timelines around on-going research, etc. which might affect the scheduling of this review should we go ahead with the proposal following this consultation. 

Please note all comments received will be published on the Institute’s website when a decision has been made.

August 2009

This page was last updated: 30 December 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.